InvestorsHub Logo
Followers 11
Posts 505
Boards Moderated 0
Alias Born 01/06/2013

Re: None

Sunday, 09/25/2016 5:16:45 PM

Sunday, September 25, 2016 5:16:45 PM

Post# of 466015
No direct reference to Anavex but very relevant. It is a very informative and interesting read. Jeffrey Cummings is the lead author with Paul Aisen as another author. For those who for whatever reason only read the MB to do their DD, these two doctors are on our Scientific Advisory Board. This article highlights the importance of trial design and there is a part where they speak of adaptive trials. Very interesting as what they speak of kind of resembles the journey we are embarking. It is not a short read so put the pot of coffee on and get a bit more educated. This was only published a few days ago so it is inline with most current ideas.

https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0207-9

Furthermore, I want to add for those hating on Missling, compare the corporate presentations from 2013 when he was hired to the most recent one.

2013 Fall
https://www.sec.gov/Archives/edgar/data/1314052/000106299313005532/exhibit99-1.htm

2016 Spring (fall coming out in a couple days)
http://www.anavex.com/files/Anavex_Presentation_Spring_2016.pdf


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News